Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Mok Tony S. K.; Kim Sang-We; Wu Yi-Long; Nakagawa Kazuhiko; Yang Jin-Ji; Ahn Myung-Ju; Wang Jie; Yang James Chih-Hsin; Lu You; Atagi Shinji; Ponce Santiago; Shi Xiaojin; Rukazenkov Yuri; Haddad Vincent; Thress Kenneth S.; Soria Jean-Charles

首页> 外文期刊>Journal of Clinical Oncology >Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

【24h】

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

机译：Gefitinib Plus化疗与化疗在表皮生长因子受体突变阳性非小细胞肺癌耐致力于第一线Gefitinib（令人印象深刻）：总体存活和生物标志物分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2017年第36期|共10页
作者
Mok Tony S. K.; Kim Sang-We; Wu Yi-Long; Nakagawa Kazuhiko; Yang Jin-Ji; Ahn Myung-Ju; Wang Jie; Yang James Chih-Hsin; Lu You; Atagi Shinji; Ponce Santiago; Shi Xiaojin; Rukazenkov Yuri; Haddad Vincent; Thress Kenneth S.; Soria Jean-Charles;
展开▼
作者单位

Chinese Univ Hong Kong Prince Wales Hosp Sha Tin Hong Kong Peoples R China;

Univ Ulsan Coll Med Ulsan South Korea;

Guangdong Gen Hosp Guangzhou Guangdong Peoples R China;

Kindai Univ Osaka Japan;

Guangdong Gen Hosp Guangzhou Guangdong Peoples R China;

Sungkyunkwan Univ Sch Med Seoul South Korea;

Peking Univ Sch Oncol Beijing Canc Hosp &

Inst Beijing Peoples R China;

Natl Taiwan Univ Hosp Taipei Taiwan;

Sichuan Univ Chengdu Sichuan Peoples R China;

Kinkichuo Chest Med Ctr Osaka Japan;

Hosp Univ 12 Octubre Madrid Spain;

AstraZeneca Shanghai Peoples R China;

AstraZeneca Cambridge England;

AstraZeneca Royston England;

AstraZeneca Waltham MA USA;

Gustave Roussy Canc Campus Villejuif France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses [J] . Mok Tony S. K., Kim Sang-We, Wu Yi-Long, Journal of Clinical Oncology . 2017,第36期

机译：Gefitinib Plus化疗与化疗在表皮生长因子受体突变阳性非小细胞肺癌耐致力于第一线Gefitinib（令人印象深刻）：总体存活和生物标志物分析
2. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study [J] . Ecological restoration . 2020,第2期

机译：吉非替尼单独对吉替尼加上非小细胞肺癌的化疗，具有突变表皮生长因子受体：NEJ009研究
3. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong [J] . LeeV.W.Y., SchwanderB., LeeV.H.F. Hong Kong medical journal =: Xianggang yi xue za zhi . 2014,第3期

机译：厄洛替尼和吉非替尼在一线治疗表皮生长因子受体激活突变阳性非小细胞肺癌患者的一线治疗的有效性和成本效益
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma: A Case-Control Study [O] . Nan-Jie Zhao, Zhao Sun, Yuzhou Wang, 2014

机译：吉非替尼整合方案与单纯化疗对重度表皮生长因子受体突变的肺腺癌患者的病例对照研究

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

摘要

著录项

相似文献

相关主题

期刊订阅